Cytori Therapeutics, Inc. (CYTX) today provided an update on the development of its proprietary drug, ATI-1123, based on recently obtained feedback from the United States Food and Drug Administration (FDA). ATI-1123 is a substantially redesigned and reformulated new drug based in part, on the active pharmaceutical ingredient, docetaxel. The purpose of the Company’s submission was to clarify certain key aspects of the future development plan including: (1) the suitability of the 505(b)(2) pathway for approval of the proposed ATI-1123 drug product, including the proposed listed drug (LD), (2) the adequacy of the referenced clinical, nonclinical and pharmaceutical quality information, in combination with the proposed drug development program, to support the new drug application and (3) any concerns that the FDA may have with regard to other filing issues specific to the product.
SAN DIEGO, June 19, 2019 -- Cytori Therapeutics, Inc. (Nasdaq: CYTX) today announced that it reconvened its annual meeting of stockholders on Tuesday, June 18, 2019 and.
Cytori Therapeutics, Inc. (CYTX) (the “company”) announced yesterday a new direction and identity. Since the beginning of 2019, the company has successfully evaluated and transformed its pipeline to place a stronger emphasis on product candidates that can maximize returns for shareholders and make a clinically meaningful impact for patients. Plus Therapeutics, Inc. plans to create and realize this value by developing drugs for niche and orphan markets, initially in oncology, that address significant unmet or substantially underserved medical needs and that represent global revenue opportunities estimated to be $250 million or more.
Q4 2019 Plus Therapeutics Inc Earnings Call
Thinly traded nano-cap biotech Cytori Therapeutics Inc (NASDAQ: CYTX ), which has been trading in penny stock territory for about a year now, could see some activity in the wake of a company announcement ...
Cytori Therapeutics, Inc. (CYTX) today announced that it reconvened its annual meeting of stockholders on Thursday, June 27, 2019 and adjourned the meeting until Thursday, July 11, 2019, at 9:00 a.m., Central Time. The annual meeting was adjourned to allow the Company’s stockholders an additional opportunity to evaluate Proposal 4, relating to the approval of a reverse stock split of the Company’s common stock. Although more than 69% of the votes cast were in favor of the reverse stock split (Proposal 4), this constitutes approximately 48% of the Company’s outstanding shares of common stock and approval requires the affirmative vote of a majority of the outstanding shares of common stock. The annual meeting was adjourned until 9:00 a.m., Central Time, on July 11, 2019 at 4200 Marathon Blvd., Suite 200, Austin Texas 78756, the Company’s offices in Austin, Texas.
Q1 2020 Plus Therapeutics Inc Earnings Call
SAN DIEGO, June 13, 2019 -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) “the Company” will provide a live webcast to discuss its continued transformation efforts following two.
SAN DIEGO, July 11, 2019 -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) “the Company” will provide a live webcast to discuss its new company direction following two recent asset.
Q3 2019 Plus Therapeutics Inc Earnings Call
Cytori Therapeutics, Inc. (CYTX) today announced that it convened its annual meeting of stockholders on Tuesday, May 28, 2019 and adjourned the meeting until Tuesday, June 18, 2019, at 9:00 a.m., Pacific Time. The annual meeting was adjourned to allow the Company’s stockholders an additional opportunity to evaluate Proposal 4, relating to the approval of a reverse stock split of the Company’s common stock. Although more than 64% of the votes cast were in favor of the reverse stock split (Proposal 4), approval requires the affirmative vote of a majority of the outstanding shares of common stock. Stockholders that have yet to vote are requested to do so prior to the new June 18 meeting date and are encouraged to vote in favor of the reverse stock split as outlined in the Company’s proxy materials.
Marc Hedrick became the CEO of Cytori Therapeutics, Inc. (NASDAQ:CYTX) in 2014. First, this article will compare CEO...